TITLE

Review: Chemotherapy and hormonal therapy reduce recurrence and mortality at 15 years in early breast cancer: COMMENTARY

AUTHOR(S)
Smith, Thomas J.; Khatcheressian, James
PUB. DATE
November 2005
SOURCE
ACP Journal Club;Nov/Dec2005, Vol. 143 Issue 3, p58
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article comments in a study which found chemotherapy and hormonal therapy reduce recurrence and mortality at 15 years in early breast cancer. In this case, the absolute benefit can be as high as 10 additional women alive per 100 treated, with no additional deaths from treatment-related diseases. These are the minimal effects of adjuvant therapy, too, because current treatments are more effective and less toxic. Recent large RCTs show that the addition of paclitaxel to 4 cycles of doxorubicin-cyclophosphamide adds another 2 to 3 survivors per 100 women. Aromatase inhibitors improve disease-free survival more than tamoxifen alone, or when given after tamoxifen, and will probably improve overall survival.
ACCESSION #
18925724

 

Related Articles

  • DETERIORO COGNITIVO INDUCIDO POR LOS TRATAMIENTOS ONCOLÓGICOS SISTÉMICOS EN EL CÁNCER DE MAMA NO METASTÁTICO: REVISIÓN DE ESTUDIOS. Rubio, Beatriz; Sirgo, Agustina; Forcadell, Eva; Mele, Mireia; Guma, Josep // Psicooncologia;2009, p83 

    Breast cancer women complain of cognitive problems after systemic oncological treatments. This has lead to study the effect of these treatments on the cognitive functioning of these patients. Aims and Method: To expose the conclusions obtained about cognitive impairment induced by systemic...

  • Radioterapia e Hormonoterapia a Título Neoadjuvante no Carcinoma Localmente Avançado da Mama: Estado da Arte. PADILHA, Marisa; HENRIQUES, Mónica; GUARDADO, Maria João; MIRANDA, Cristina; MELO, Gilberto; ALVES, Paula // Acta Medica Portuguesa;nov-dez2012, Vol. 25 Issue 6, p422 

    Introduction: Breast cancer is a health problem of great magnitude. In recent years we have seen an increasing incidence and decreasing mortality from this disease due to implementation of campaigns for early diagnosis and the effectiveness of existing treatments. For more than a century that we...

  • Breast cancer in moroccan young women: a retrospective study. Abahssain, Halima; Lalya, Issam; M'Rabet, Fatima zahra E. L.; Ismaili, Nabil; Razine, Rachid; Tazi, Mohammed Adnane; M'rabti, Hind; El Mesbahi, Omar; Benjaafar, Nourddine; Abouqal, Redouane; Errihani, Hassan // BMC Research Notes;2010, Vol. 3, p286 

    Background: Breast cancer is uncommon in young women and induces more aggressive biologic characteristics. Survival in young women has been widely studied in developed countries. Less favorable prognosis and low survival were found. In Morocco, this study is the first investigation of clinical...

  • Review: Chemotherapy and hormonal therapy reduce recurrence and mortality at 15 years in early breast cancer.  // ACP Journal Club;Nov/Dec2005, Vol. 143 Issue 3, p58 

    This article presents information on a clinical study which found that chemotherapy and hormonal therapy reduce recurrence and mortality at 15 years in early breast cancer. Unconfounded randomized controlled trials (RCTs) of adjuvant systemic therapies for early breast cancer begun before 1995....

  • Fulvestrant in advanced male breast cancer. Rodríguez, J. R. de la Haba; Quintela, I. Porras; Cortijo, G. Pulido; Guerrero, M. Berciano; Aranda, E. // Annals of Oncology;Nov2009, Vol. 20 Issue 11, p1896 

    A case report of fulvestrant in advanced male breast cancer is presented. Treatment with fulvestrant was begun after the patient did not respond to chemotherapy. After four months of fulvestrant, computed tomography (CT) scans showed reduction of the pulmonary lesions and pleural effusion. The...

  • Thirty-year follow-up of chemo/hormonal therapy in node-positive breast cancer. P. Silverman; W. Lasheen; J. Meinert // Breast Cancer Research & Treatment;May2007, Vol. 102 Issue 3, p301 

    Abstract  Results of a thirty-year follow-up of a clinical trial of chemo-hormonal therapy are reported. Eligible patients had recently diagnosed operable breast cancer, positive lymph nodes, no previous history of cancer, age less than 76 years, and no evidence of metastatic disease. A...

  • Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women. Chlebowski, Rowan T.; Kuller, Lewis H.; Prentice, Ross L.; Stefanick, Marcia L.; Manson, JoAnn E.; Gass, Margery; Aragaki, Aaron K.; Ockene, Judith K.; Lane, Dorothy S.; Sarto, Gloria E.; Rajkovic, Aleksandar; Schenken, Robert; Hendrix, Susan L.; Ravdin, Peter M.; Rohan, Thomas E.; Yasmeen, Shagufta; Anderson, Garnet // New England Journal of Medicine;2/5/2009, Vol. 360 Issue 6, p573 

    Background: Following the release of the 2002 report of the Women's Health Initiative (WHI) trial of estrogen plus progestin, the use of menopausal hormone therapy in the United States decreased substantially. Subsequently, the incidence of breast cancer also dropped, suggesting a...

  • Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. Bernhard, J.; Zahrieh, D; Coates, A S; Gelber, R D; Castiglione-Gertsch, M; Murray, E; Forbes, J F; Perey, L; Collins, J; Snyder, R; Rudenstam, C-M; Crivellari, D; Veronesi, A; Thürlimann, B; Fey, M F; Price, K N; Goldhirsch, A; Hürny, C // British Journal of Cancer;11/29/2004, Vol. 91 Issue 11, p1893 

    We evaluated quality of life (QL) and quality-adjusted survival in International Breast Cancer Study Group Trial IX, a randomised trial including 1669 eligible patients receiving tamoxifen for 5 years or three prior cycles of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) followed by 57...

  • Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators. Schiff, Rachel; Massarweh, Suleiman A.; Jiang Shou; Bharwani, Lavina; Arpino, Grazia; Rimawi, Mothaffar; Osborne, C. Kent // Cancer Chemotherapy & Pharmacology. Supplement;Nov2005, Vol. 56, p10 

    Estrogen receptor (ER), mediating estrogen-signaling stimuli, is a dominant regulator and a key therapeutic target in breast cancer etiology and progression. Endocrine therapy, blocking the ER pathway, is one of the most important systemic therapies in breast cancer management, but de novo and...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics